Thomas W. Comollo, Ph.D.
Thomas W. Comollo, Ph.D., possesses research strengths in both theoretical / computational studies and the experimental (“wet”) laboratory.
Comollo teaches Immunology at Kean University. He also has research experience in structure-based drug discovery / molecular modeling, ion channel molecular physiology and pharmacology. He performed his PhD thesis at Rutgers University – New Jersey Medical School on gamma subunits of voltage gated calcium channels. He performed postdoctoral work at Columbia University – School of Physicians and Surgeons and Rutgers University – New Jersey Medical School were his research included ion channels, electrophysiology and calcium handling in the heart.
More recently, Comollo has performed structure-based drug discovery and enzymatic assays in search of anti-SARS-CoV-2 therapeutics. SARS-CoV-2 is the virus that causes COVID19. This work was done as part of Dr. Comollo’s company he has as a “hobby”, FSDP LLC (https://home.fatsilicodatapharm.com/), and in conjunction with Virendra Pandey’s laboratory at Rutgers University – New Jersey Medical School. Not-for-profit portions of the project were funded by the Gaokerena Institute (https://www.gaokerenainstitute.org/).
Comollo has a patent and patent application from drug discovery efforts and has been published in journals such as Biochemistry and Scientific Reports. He believes he can help students to achieve greater things.
Comollo, T.W., 2021. Method for Treating COVID-19 and Related Viral Infections. US Patent Application 17/472,647.
Comollo, T.W., Zhang, C., Zou, X. and Kass, R.S., 2020. Physiology and Molecular Biology of Ion Channels Underlying Ventricular Repolarization of the Mammalian Heart. In Cardiac Repolarization(pp. 3-47). Springer, Cham.
Welsh, W.J., Birge, R., Kholodovych, V., Peng, Y., Comollo, T.W., Kimani, S.G. and Singh, K., Rutgers State University of New Jersey and University of Missouri System, 2020. Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents. U.S. Patent 10,851,096.
Kimani, S.G., Kumar, S., Bansal, N., Singh, K., Kholodovych, V., Comollo, T., Peng, Y., Kotenko, S.V., Sarafianos, S.G., Bertino, J.R. and Welsh, W.J., 2017. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity. Scientific reports, 7(1), pp.1-11.
Comollo, T.W., 2018. Molecular Modeling Suggests Homologous 2-APB Binding Sites in Connexins 26 and 32. bioRxiv, p.287326.